Skip to content

Medical emergency? What to do

Early Heart Data Look Good for Obesity Drug

3-RXPublished November 27, 20133 min read

Key points

  • Interim data from a cardiovascular safety study of an investigational weight-loss agent have met FDA criteria, and drugmaker Orexigen Therapeutics will seek to resubmit the drug for U.S. approval.
  • The drug was denied FDA approval in February 2011, even though an advisory committee had voted largely in favor of approval.
  • Orexigen said it plans to do so soon, with plans for U.S. approval of the drug by June 2014.
  • Louis Aronne, MD, of Weill-Cornell Medical College in New York City, said the findings are "promising."

Interim data from a cardiovascular safety study of an investigational weight-loss agent have met FDA criteria, and drugmaker Orexigen Therapeutics will seek to resubmit the drug for U.S. approval.

A company press release reported that the combination of naltrexone and bupropion (Contrave) didn't double the risk of major adverse cardiovascular events (MACE) compared with placebo - a requirement set by the FDA - in an interim look at data from the Light Study, a cardiovascular outcomes trial.

The drug was denied FDA approval in February 2011, even though an advisory committee had voted largely in favor of approval. The agency required that the company conduct a cardiovascular outcome trial before it would approve the drug.

It also agreed that if the study could exclude a doubling of the risk of MACE with the drug compared with placebo, the company could submit the interim analysis for consideration in a resubmitted new drug application (NDA).

Orexigen said it plans to do so soon, with plans for U.S. approval of the drug by June 2014. It also submitted a Marketing Authorization Application to the European Medicines Agency in October 2013, with hopes for approval there by the second half of 2014.

The company also reported no new safety signals in the Light Study, which randomized about 8,900 patients from 260 clinical sites across the country.

Louis Aronne, MD, of Weill-Cornell Medical College in New York City, said the findings are "promising."

"What one would really like to see is a reduction in cardiovascular risk," Aronne told MedPage Today. "If risk of Contrave is increased but not to double the placebo risk, it could be approved -- but it would not inspire confidence once on the market."

He added that the diabetes drug liraglutide (Victoza) is also being investigated as a weight-loss agent and may hold promise as a treatment for obesity.

"We clearly need more medications for the treatment of obesity," he said, "that's for certain."

Steven Smith, MD, president of the Obesity Society, said in a statement that Contrave, if approved, could be a useful part of the obesity treatment toolbox.

"Obesity medications provide an additional tool for obesity clinicians and produce the most weight loss when combined with diet and exercise," Smith said, cautioning, however, that the drugs are "not for everyone, and they are not for short-term weight loss."

"These obesity medications are no different from others approved by the FDA, requiring a thorough physician assessment of each individual patient and continued monitoring of health for success," he said.

Smith noted that "given the complex nature of obesity, there is no magic bullet" and society needs to support research for more effective weight loss strategies and drugs: "Currently, there are more than 100 drugs for hypertension, yet only two approved for long-term use for obesity."

###

By Kristina Fiore, Staff Writer, MedPage Today

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Food & Nutrition

Soda & Obesity

There is a new assault on sodas and other sugar-sweetened beverages, with multiple studies linking them to unnecessary weight gain. 15-year-old Maggie Caudill has entered a weight loss program at Boston Children's…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.